,16 Given the preeminent role of TGF-β in the tumor microenvironment,17 this intriguing finding raises the possibility that Vγ9Vδ2 T cells expanded in TGF-β could exploit a key node of tumor-associated immunosuppression for therapeutic benefit. The gene discussed is TGFB1; the disease is neoplasm.